RG 012

Drug Profile

RG 012

Alternative Names: RG012; SAR 339375

Latest Information Update: 06 Mar 2017

Price : $50

At a glance

  • Originator Regulus Therapeutics; Sanofi
  • Developer Regulus Therapeutics
  • Class Antisense oligoribonucleotides
  • Mechanism of Action MicroRNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary nephritis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hereditary nephritis

Most Recent Events

  • 02 Mar 2017 Regulus Therapeutics plans a phase I/II renal biopsy pharmacokinetics trial in Hereditary nephritis patients
  • 01 Dec 2016 Regulus Therapeutics initiates a phase I multiple ascending dose trial in healthy volunteers
  • 01 Aug 2016 Phase-II clinical trials in Hereditary nephritis in USA (SC) (NCT02855268)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top